Abstract 6P
Background
Neoadjuvant chemotherapy (NAC) results in a pathologic complete response (pCR) and is associated with disease-free survival and overall survival. The apparent diffusion coefficient (ADC) indicates the stability of water molecules and is used to predict the response of solid tumors to chemotherapy. Therefore, we evaluated the changes in ADC using diffusion-weighted breast magnetic resonance imaging (MRI) to predict pCR in patients with breast cancer treated with NAC.
Methods
From August 2013 to April 2019, 50 patients (mean age, 55 years; age range, 31–75 years) were treated with nanoparticle albumin-bound paclitaxel (nab-PTX) (260 mg/m2) every 3 weeks for four cycles ± concurrent trastuzumab (8 mg, 6 mg/kg) every 3 weeks for four cycles in human epidermal growth factor receptor 2 (HER2)-positive patients followed by FEC (5-fluorouracil/epirubicin/cyclophosphamide, 500/100/500 mg/m2) every 3 weeks for four cycles. pCR was defined as the absence of any residual invasive cancer or ductal carcinoma in situ in the breast. Changes in ADC (Δnab-PTX: post nab-PTX – pre nab-PTX, ΔFEC: post FEC – pre nab-PTX) were also calculated.
Results
The tumor phenotypes were triple negative (TN) (n = 25) and HER2 positive (n = 25). pCR was achieved in 27 patients [54%] (11 with TN disease and 16 with HER2-positive disease). The mean pre nab-PTX ADC and ΔFEC ADC in pCR patients were 0.718±0.157 × 10-3 mm2 and 0.621±0.357 × 10-3 mm2, respectively, and they were not associated with pCR (p = 0.06 and p = 0.248, respectively). However, the mean post nab-PTX ADC and Δnab-PTX ADC were 1.117±0.303 × 10-3 mm2 and 0.400±0.311 × 10-3 mm2, respectively, and they were associated with pCR (p < 0.01 and p = 0.01, respectively). Using receiver operating characteristic (ROC) analysis with Δnab-PTX ADC, the area under the curve was 0.691 [95% confidence interval: 0.54–0.841] in all patients. Δnab-PTX ADC and pCR were significantly correlated (p = 0.00463).
Conclusions
High Δnab-PTX ADCs in diffusion-weighted breast MRI may be promising findings for the successful prediction of pCR in patients treated with NAC using nab-PTX followed by FEC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract